| Name | Title | Contact Details |
|---|
Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. We are focused on ophthalmology and urology drug therapies; however we also sell other formulations outside of our core ophthalmology and urology therapeutic areas. All of our innovative drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators. We believe our unique business model provides us with the opportunity to address unmet patient needs while delivering safe, near-term and affordable medical solutions to Americans. We have made tremendous progress since the launch of our ophthalmology business and our Go Dropless™ educational campaign in April 2014. Our ophthalmology business is disrupting the billion dollar eye drop market as physicians are adopting Dropless Therapy™ for their patients. We recently announced the availability of our LessDrops™ proprietary topical combination eye drops for post LASIK and other ocular surgeries. During first quarter 2015, we launched our urology business, entering the multi-billion dollar interstitial cystitis (IC) market. In connection with our urology launch, we will commercialize our patented Hep-Lido-A formulation and promote the Defeat IC™ educational campaign focused on medical practitioners and the estimated ten million women and men in the U.S. chronically affected by IC and PBS. We are committed to customer relations, highest quality standards, accessible innovation and solving the unmet needs in the markets we serve. We are delivering on the promise of our unique model and look forward to continuing to serve the needs of our customers with additional novel drug therapies in our product portfolio, and in turn grow our business. Our hope is that through the success of our business we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.
netpharmaworld is a Addison, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Today`s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck`s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.
Part of UK-based Bio Products Laboratory, BPL Plasma has been a global leader in the plasma collection industry for more than 25 years. We`re proud to support the creation & manufacturing of lifesaving drug therapies by supplying high-quality plasma to people in need. At BPL Plasma, the people who walk into our centers are much more than donors — they are lifelines. Their donation, quite literally, transforms the lives of patients around the planet. Donating plasma makes it possible for: - An expectant mother to carry her child safely to term. - A little boy with hemophilia to experience a healthy, happy childhood. - A wounded warrior or burn victim to begin the healing process.